News

Earlier, the agency has accepted the company’s investigational new drug (IND) application for a Phase I/II open-label, dose-escalating trial of PRTX-100 in adults with persistent/chronic ITP. The company

Dextenza (sustained release dexamethasone, 0.4mg) is administered by a physician as a bioresorbable intracanalicular depot for drug release to the ocular surface for up 30 days. People who

The initiation of the placebo-controlled, dose-finding trial follows clearance from the US Food and Drug Administration (FDA) of the company’s investigational new drug (IND) application for HTX-011. HTX-011,

The new facility will manufacture packaging components for insulin injector cartridges and other high-value packaging components for injectable drugs. The 95,000ft² facility will be built at a 44-acre

The deal will see the two parties jointly work to develop new drugs to treat serious back-of-the-eye diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic

Through its relationship with NHS, Mesa’s revenue has grown significantly over the past six months. NHS is building on its mutually beneficial relationship and taking on a more

AVA-101 also showed an improvement on best corrected visual acuity (BCVA) compared with the control group and a positive trend in response rate (stable vision with few rescue

Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy

The Company has licensed an AAV gene therapy and IP from the University of Minnesota to treat patients with Fanconi anemia (FA) disorder and other rare blood diseases.